Instrument overview
GMABGenmab A/S
StockNasdaqDenmarkHealth careEU retail: available
+28.3% today · +96.7% over a year
No score: too little data.
Trend: among the best of its peers. No dividend.
Genmab A/S (GMAB) belongs to the Health care sector and is listed on Nasdaq; country: Denmark. Over the past 12 months the price changed by +96.7%, with an annualised volatility of 43% and a largest fall of 33%.
Smart Score
How it is scored →Not scored: not enough data for a fair comparison.
Factor scores
Profitability, balance-sheet safety, growth and capital discipline versus peers. More in the glossary →better than 69% of peers
Price trend over the last 12 and 6 months (excluding the last month) and distance from the 52-week high. More in the glossary →better than 90% of peers
Lower price swings, lower market sensitivity (beta) and shallower drawdowns score higher. More in the glossary →better than 32% of peers
Percentiles within the peer group (100 = the best of its peers); dividend safety in points.
Main drivers
- Share issuance (1 y)supports the score · better than 75% of peers
- Return on invested capitalsupports the score · better than 83% of peers
- Price / 52-week highsupports the score · better than 96% of peers
Red flags and notes
No red flagsNone of our published warning rules is triggered right now.
Price chart
Interactive chart by TradingView: exchange prices are delayed, crypto and currencies are live.
Key metrics
Profitability and debt
- Return on equity
- 17.5%
- Return on invested capital
- 12.9%
- Gross margin
- 93.6%
- Net debt / EBITDA
- 3.13
Dividends
- Dividend yield
- 0.00%
- Years of dividend growth
- 0
Returns and risk
- 1 day
- +28.3%
- 1 month
- +62.0%
- 1 year
- +96.7%
- Volatility, 1 yr
- 42.9%
- Max drawdown, 1 yr
- −32.5%
- Beta
- 0.92
Ratios from SEC filings and end-of-day prices; returns are price changes without dividends.
Similar companies
Same sector, closest in price swings over the past year.
| 2359WuXi AppTec | —/10 | 1.3% | 71.8% |
|---|---|---|---|
| 7733Olympus Corp. | —/10 | 1.7% | −6.3% |
| 3692Hansoh Pharmaceutical | —/10 | 1.5% | −5.7% |
| BAYNBayer AG | —/10 | 0.2% | 68.2% |
| 6618JD Health International | —/10 | 0.0% | −41.4% |
| 241Alibaba Health Information Technology | —/10 | 8.1% | −50.1% |
| 1177Sino Biopharmaceutical | —/10 | 2.5% | −29.3% |
| 2269Wuxi Biologics | —/10 | 0.0% | 26.0% |
News and filings
- GENMAB A/S: 6-K — Report of a foreign private issuer
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 28 Oct 2026
- GENMAB A/S: 6-K — Report of a foreign private issuer
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 23 Oct 2026
- GENMAB A/S: 6-K — Report of a foreign private issuer
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 13 Oct 2026
- GENMAB A/S: 6-K — Report of a foreign private issuer
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 7 Oct 2026
- GENMAB A/S: 6-K — Report of a foreign private issuer
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 5 Oct 2026
- GENMAB A/S: 6-K — Report of a foreign private issuer
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 2 Oct 2026
- GENMAB A/S: 6-K — Report of a foreign private issuer
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 29 Sep 2026
- GENMAB A/S: 6-K — Report of a foreign private issuer
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 24 Sep 2026
- GENMAB A/S: 6-K — Report of a foreign private issuer
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 9 Sep 2026
- GENMAB A/S: 6-K — Report of a foreign private issuer
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 9 Sep 2026
- GENMAB A/S: 6-K — Report of a foreign private issuer
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 8 Sep 2026
- GENMAB A/S: 6-K — Report of a foreign private issuer
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 12 Aug 2026
- GENMAB A/S: 6-K — Report of a foreign private issuer
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 11 Aug 2026
- GENMAB A/S: 6-K — Report of a foreign private issuer
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 6 Aug 2026
What the marks mean
- FactA filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.
- Media reportA headline from a named media outlet. We link to it and do not check it.
- RumourUnconfirmed: the headline itself hedges (“reportedly”, “sources say”, “in talks”), names no publisher, or comes from a news aggregator or an automated republisher.
Source: Filings: U.S. SEC EDGAR. The tone is scored automatically from the headline and can be wrong.
Score changes in the last 12 months
Every published rating and change, logged when it was published (EU Market Abuse Regulation).
No published ratings in the last 12 months.
Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.